TRAF3IP2 and glioblastoma: To investigate the role of TRAF3IP2 in the tumorigenicity of malignant U87 glioblastoma cells, we injected TRAF3IP2-silenced U87 cells (U87TRAF3IP2KD cells) into the flank region of immunodeficient NIH-III mice and followed for up to 60 days.